Compare MLSS & NEUP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MLSS | NEUP |
|---|---|---|
| Founded | 1989 | 1996 |
| Country | United States | United States |
| Employees | N/A | 8 |
| Industry | Industrial Specialties | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 22.1M | 23.8M |
| IPO Year | 1996 | N/A |
| Metric | MLSS | NEUP |
|---|---|---|
| Price | $0.28 | $4.72 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | $1.00 | ★ $21.00 |
| AVG Volume (30 Days) | ★ 996.3K | 47.8K |
| Earning Date | 05-14-2026 | 05-23-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $8,973,982.00 | N/A |
| Revenue This Year | $12.64 | N/A |
| Revenue Next Year | $8.99 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 3.99 | N/A |
| 52 Week Low | $0.22 | $3.65 |
| 52 Week High | $1.11 | $21.31 |
| Indicator | MLSS | NEUP |
|---|---|---|
| Relative Strength Index (RSI) | 47.90 | 59.82 |
| Support Level | $0.27 | $3.91 |
| Resistance Level | $0.30 | $5.06 |
| Average True Range (ATR) | 0.02 | 0.26 |
| MACD | -0.00 | 0.04 |
| Stochastic Oscillator | 38.04 | 100.00 |
Milestone Scientific Inc develops and commercializes proprietary computer-controlled drug delivery systems designed to enhance the safety, precision, and patient experience associated with subcutaneous injections and fluid aspiration procedures. The company's core technology platform, Dynamic Pressure Sensing (DPS) Technology, controls flow rate and measures pressure at the needle tip in real time. DPS Technology is incorporated into both the company's dental and medical products and supports clinical applications, including local anesthesia delivery, epidural space identification in regional anesthesia procedures, and intra-articular joint injections. It operates in two segments: Dental, which markets and sells its dental products, and Medical, markets and sells its medical products.
Neuphoria Therapeutics Inc is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company is advancing its drug candidate, BNC 210, an oral, proprietary, selective negative allosteric modulator of the Alpha7 nicotinic acetylcholine receptor, for the acute treatment of social anxiety disorder and for chronic treatment of post-traumatic stress disorder. The Company operates through a single operating and reportable segment focused on the discovery and development of allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system (CNS) disorders with high unmet medical need.